Human lungs are delicate organs and are
the main portal for entry and exit of aerosolized materials and gases.
Therefore, understanding of the interaction of aerosolized materials
with the lung cells is of great interest in the field of human health.
Animal testing is still the most prevalent model used to study various
diseases, new drug development, and for risk assessment. However, in
order to reduce animal experimentation, a need has arisen for realistic
and well-accepted in vitro alternatives. In vitro lung model can be
established by culturing macrophages, epithelial cells, and dendritic
cells favorable for culture medium. It has been demonstrated that the
developed in vitro lung model mimics like lung tissue, in terms of
physiology and functionality, in vivo and the cell-cell interactions in
this system permit a predictive in vitro screening.
The global in vitro lung model market can be segmented on the basis
of type, application, and geography. On the basis type, the global in
vitro lung model market can be divided into 2D cell models and 3D cell
models. The 2D cell models segment is expected to hold the maximum share
of the market during the forecast period. The 3D cell models segment is
projected to expand at a significant CAGR during forecast period due to
the rise in demand for efficient in vitro lung model that mimic greater
in vivo physiology. The 3D cell model segment can be sub-segmented into
in-house and commercial. In terms of application, the global in vitro
lung model market can be categorized into drug screening &
toxicology, basic research, 3D model development, physiologic research,
stem cell research, and regenerative medicine. The drug screening &
toxicology segment is expected to expand at a significant CAGR during
the forecast period due to increase in research and development of new
drugs and rising demand for in vitro lung model. Technological
advancement, increase in research and development budget, and rise in
focus on developing alternatives to animal testing are the factors
projected to boost the growth of the market during the forecast period.
However, high cost of the in vitro model and lack of awareness are
anticipated to hamper the global market during the forecast period.
Geographically, the global in vitro lung model market can be
segmented into five regions, North America, Latin America, Europe, Asia
Pacific, and Middle East & Africa. North America is anticipated to
be the dominant market for in vitro model, followed by Europe. Presence
of key market players, well-established health care infrastructure,
increase in research funding from various organizations, and rise in
research and development activities by various pharmaceutical and
biotechnology companies propel the growth of the global in vitro lung
model market in North America and Europe. The in vitro lung model market
in Asia Pacific is expected to expand at a significant CAGR during the
forecast period, driven by India and China, due to the rising focus of
major players on the untapped market in these countries, coupled with
growing awareness, increased government initiatives, and developing
health care infrastructure. The in vitro lung model market in Latin
America and Middle East & Africa is anticipated to grow
significantly during the forecast period owing to the increasing
investments made by market players in these regions.
Leading players operating in the global in vitro lung model market
include MatTek Corporation, Epithelix, Lonza, ATCC, AlveoliX, InSphero,
CN Bio Innovations, Emulate, Insphero, TissUse, Oncotheis, and Mimetas.
No comments:
Post a Comment